ABOUT THIS EVENT

Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, rang the Nasdaq Closing Bell remotely from across the country.

Paul J. Hastings, President and CEO of Nkarta, rang the Closing Bell alongside the Company’s team in a virtual bell ringing ceremony.